-------- Original Version -----------
Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients-------- English Version ------------
Grünenthal announced that it has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-based innovation network bringing together universities, research institutions, biotech companies, and industry partners to accelerate nucleic acid therapeutics into innovative treatments for patients.-------- Link if available ----------